CSL Behring – Withdrawal of Hizentra® [immune globulin subcutaneous (human)]
On December 30, 2021 CSL Behring announced a patient-level withdrawal of one lot of Hizentra [immune globulin subcutaneous (human)] due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration.
Top